Cystic fibrosis: nutritional consequences and management.
Life expectancy for patients with Cystic Fibrosis (CF) has steadily improved during the last three decades, and death in childhood is now uncommon. Nutrition is a critical component of the management of CF, and nutritional status is directly associated with both pulmonary status and survival. Expert dietetic care is necessary, and attention must be given to ensuring an adequate energy intake in the face of demands which may be increased by inadequately controlled malabsorption, chronic broncho-pulmonary colonisation by bacteria and fungi, exacerbations of acute lung infection, impaired lung function, and the need for rehabilitation, repair and growth. Pancreatic enzyme replacement therapy (PERT) is needed by up to 90% of CF patients in Northern Europe, where the 'severe' mutation deltaF508 predominates, but a smaller proportion in Mediterranean countries and elsewhere, because pancreatic insufficiency is one of few features of CF which correlate with genotype. Complications of CF including liver disease and CF-related diabetes pose further challenges. In addition, deficiency of specific nutrients including fat soluble vitamins (particularly A, E and K) essential fatty acids and occasionally minerals occur for a variety of reasons. Osteopenia is common and poorly understood. Liver disease increases the likelihood of vitamin D deficiency. Glucose intolerance and diabetes affect at least 25% of CF adults, and the diabetes differs from both types 1 and 2 diabetes mellitus, but it inversely correlates with prognosis. Management consists of anticipating problems and addressing them vigorously as soon as they appear. Supplements of vitamins are routinely given. Energy supplements can be oral, enteral or, rarely, parenteral. All supplements, including PERT, are adjusted to individual needs.
Dodge
John A
JA
Singleton Hospital, University of Wales Swansea, Swansea SA2 8QA, UK. j.a.dodge@btinternet.com
Turck
Dominique
D
D000328:Adult; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000503:physiopathology; D019587:Dietary Supplements; D004750:Enteral Nutrition; D005228:Fatty Acids, Essential / Q000172:deficiency; D006801:Humans; D006867:Hydrolases / Q000627:therapeutic use; D044342:Malnutrition / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D010288:Parenteral Nutrition
D005228:Fatty Acids, Essential; D006867:Hydrolases